Consensus Bio-Path Holdings, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
3 ^USD	+10.70%		+6.01%	-67.60%

Apr. 19	Bio-Path Closes $1.2 Million Share Offering	MT
Apr. 18	Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	CI

04.AXWaun6RLEycens5V4c0No9DvpOuYbEp7eyKZ71IOAU.aET3w0qoQSnNHwJcEMEFWuwc9t3UNukduZXbCdYsCEdVGvONEPwUKf8OSw~a8059243f3a899f540dbb45e721f04d5

HC Wainwright Adjusts Price Target on Bio-Path Holdings to $9 From $12, Reiterates Buy Rating	22-05-19	MT
BIO PATH : HC Wainwright Adjusts Price Target on Bio-Path Holdings to $12 From $10, Maintains Buy Rating	21-04-06	MT
BIO PATH : Roth Capital Starts Bio-Path Holdings at Buy With $13 Price Target	21-03-11	MT
BIO PATH : HC Wainwright Adjusts Bio-Path Holdings' Price Target to $10 from $12, Keeps Buy Rating	20-11-16	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3 USD

Average target price

40 USD

Spread / Average Target

+1,233.33%

High Price Target

40 USD

Spread / Highest target

+1,233.33%

Low Price Target

40 USD

Spread / Lowest Target

+1,233.33%

HC Wainwright
Roth Capital Partners